Epizyme (EPZM) Misses Q3 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. SBUX
9. SNDK
10. MA

Go back to Epizyme (EPZM) Misses Q3 EPS by 3c

Epizyme (EPZM) Reports Publication of EPZ-5676 Data

November 6, 2014 7:34 AM EST

Epizyme (NASDAQ: EPZM) announced the publication on the website of the American Society of Hematology (ASH) of an abstract entitled The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia. The abstract contains preliminary data from the Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). EPZ-5676 is being developed for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The Company plans to present updated data... More